ArticleFrontiers in oncology2026
The impact of HER2 discordance on patient prognosis following anti-HER2 neoadjuvant therapy for HER2-positive breast cancer.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Human epidermal growth factor receptor 2 (HER2) discordance between biopsy and residual disease (RD) is common in HER2-positive breast cancer (BC) after anti-HER2 neoadjuvant therapy (NAT). This study investigated the impact of HER2 discordance on oncological outcomes. Methods: Consecutive HER2-positive BC patients who received anti-HER2 NAT were identified from a prospective database. HER2 status was evaluated for both biopsy specimens and RD before and after NAT. The prognostic implications of HER2 discordance were assessed. Results: A total of 700 HER2-positive BC patients were enrolled, 267 (38.1%) of whom achieved pathological complete response (pCR) after NAT. For patients with RD after NAT, the HER2 status of RD was HER2 (3+) in 209 (29.9%), HER2 (2+) in 144 (20.6%), and HER2 (1+ or 0) in 80 (11.4%) patients. A total of 217 patients exhibited HER2 changes after NAT, including 183 (26.1%) cases with loss and 34 (4.9%) with gain of HER2 positivity. There was no significant difference ( Conclusion: HER2 discordance after anti-HER2 NAT was observed in a substantial proportion of HER2-positive BC patients. However, neither the change of HER2 nor the specific HER2 status after NAT was associated with the prognosis. Moreover, pre-NAT HER2 status was a robust prognostic factor in HER2-positive BC patients who received anti-HER2 NAT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.